Discriminating measures of bronchodilator drug efficacy and potency

British Journal of Clinical Pharmacology, Supplement

Volumn 52, Issue 3, 2001, Pages 245-253

  Buck, H ^a   Parry Billings, M ^a  

^a Tlic Zigyirat   (United Kingdom)

Author keywords

Airway hyperresponsiveness; Asthma; Bioequivalence; Bronchodilator; Spirometry; Whole body plethysmography; 2 adrenoceptor agonist

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT;

ASTHMA; DOSE RESPONSE; HUMAN; REVIEW; TREATMENT OUTCOME;

ADRENERGIC BETA-AGONISTS; ASTHMA; BRONCHODILATOR AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; TREATMENT OUTCOME;

EID: 0035465227     PISSN: 02643774     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0306-5251.2001.01450.x     Document Type: Article

References (71)

1. National Asthma Education and Prevention Program. Expert Panel Report 2: Guidelines for the diagnosis and management of asthma. NIH, Bethesda, MD; 1997; Publication number 97-4051: 31-70.
2. British Thoracic Society guidelines on asthma management. Tliorax 1997; 52(Suppl 1): S1-S21.
3. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. Lancet 1998; 351: 1225-1232.
4. The Montreal Protocol. The Montreal protocol on substances that deplete the ozone layer. Final Act (Nairobi: UNEP 1987). Fed Reg 1994; 59: 56276-56298.
5. Bell J. International development of portable inhalers. J Invest Allergol Clin Immunol 1997; 7: 417-419.
6. Adams WP, Poochikian G, Taylor AS, Patel RM, Burke GP, Williams RL. Regulatory aspects of modifications to innovator bronchodilator metered dose inhalers and development of generic substitutes. J Acrosol Mcd 1994; 7: 119-134.
7. Division of Bioequivalence. Office of Generic Drugs, Center for Drug Evaluation and Research, Food and Drug Administration. Interim guidance for documentation of in vivo biocqnivalencc ofalbutcrol inlialation aerosols (inctcred dose inhalers). PDA, Rockville, MD, 1994.
8. Division of Oncology and Pulmonary Drug Products, Center for Drug Evaluation and Research, Food and Drug Administration. Points to consider: clinical development programmes for MDI and DPI drug products. PDA, Rockville, MD, 1994.
9. Standardised Lung Function Testing. Official Statement of the European Respiratory Society. Eur RcspirJ 1993; 6(Suppl 16).
10. American Thoracic Society. Standardisation of spirometry - update. Am Rev Respir Dis 1987; 136: 1285-1298.
11. Newhouse MT, Nantel NP, Chambers CB, Pratt B, Parry-Billings M. Clickhaler (a novel dry powder inhaler) provides similar bronchodilation to pressurized metered-dose inhaler, even at low rates. Chest 1999; 115: 952-956.
12. Oseid S, Mellbye E, Hem E. Effect of nedocromil sodium on exercise-induced bronchoconstriction exacerbated by inhalation of cold air. ScandJ Mcd Sri Sports 1995; 5: 88-93.
13. Borgström L, Derom E, Stahl E, Wählin-Boll E, Pauwels R. The inhalation device influences lung deposition and bronchodilating effect of terbutaline. Am J Respir Crit Care Mcd 1996; 153: 1636-1640.
14. Ahrens RC. On comparing inhaled beta adrenergic agonists. Ann Allergy 1991; 67: 296-298.
15. Ahrens RC, Hendeles L, Clarke WR, et al. Therapeutic equivalence of Spiros dry powder inhaler and Ventolin metered dose inhaler: a bioassay using methacholine. AmJ Respir Crit Care Mcd 1999; 160: 1238-1243.
16. Silvasti M, Laurikainen K, Nieminen M, et al. Single dose comparison between a novel multiple dose powder inhaler and a conventional metered dose inhaler in asthmatic patients. Acta Ther 1993; 19: 125-134.
17. Bennett JA, Tattersfield AE. Time course and relative dose potency of systemic effects from salmeterol and salbutamol in healthy subjects. Thorax 1997; 52: 458-464.
18. Bennis J, Svedmyr N. A controlled comparison of salbutamol and terbutaline by IPPV in asthmatic patients: a dose-response study. ScandJ Respir Dis 1977; 101(Suppl): 113-117.
19. Finney DJ. Statistical methods in biological assay, 3rd edn. London: Charles Griffin and Co Ltd, 1978.
20. Singh GJP. Examples af assessment on the response scale and dose scale. PDA Advisor)' Committee for Pharmaceutical Science and Pulmonary-Allergy Drugs Advisory Committee Meeting, August 16, 1996.
21. Löfdahl C-G, Andersson L, Bondesson E, et al. Differences in bronchodilating potency of salbutamol in Turbuhaler" as compared with a pressurized metered-dose inhaler formulation in patients with reversible airway obstruction. Etir Respir J 1997; 10: 2474-2478.
22. Blake KV, Hoppe M, Harman E, Hendeles L. Relative amount of albuterol delivered to lung receptors from a metered-dose inhaler and nebulizer solution. Bioassay by histamine bronchoprovocation. Chest 1992; 101: 309-315.
23. Britton J, Tattersfield A. Comparison of cumulative and on-cumulative techniques to measure dose-response curves for beta agonists in patients with asthma. Tliorax 1984; 39: 597-599.
24. Morice AH, Peake MD, Alien MB, Campbell JC, Parry-Billings M. Reproducibility of bronchodilator response for a reservoir dry powder inhaler following routine clinical me. J Asthma 2000; 37: 81-87.
25. Morley TF, Marmozsan E, Zappasodi SJ, Gordon R, Griesback R, GiudiceJC. Comparison ofbeta-adrenergic agents delivered by nebulizer vs metered dose inhaler with InspirEase in hospitalized asthmatic patients. Chest 1988; 94: 1205-1210.
26. Hess D, Homey D, Snyder T. Medication-delivery performance of eight small-volume, hand-held nebulizers: effects of diluent volume, gas flowrate, and nebulizer model. Rcspir Care 1989; 34: 717-723.
27. Zainudin BMZ, Biddiscombe M, Tolfree SEJ, Short M, Spiro SG. Comparison of bronchodilator responses and deposition patterns of salbutamol inhaled from a pressurised metered dose inhaler, as a dry powder, and as a nebulised solution. Thorax 1990; 45: 469-473.
28. Youngchaiyud V, Maranetra N, Nana A, et al. Good bronchodilating effect of a dry powder inhaler in the treatment of acute asthma. Eur Respir J 1996; 9(Suppl 23): 54s.
29. Bisgaard H. Drug delivery from inhaler devices. Lung deposition, clinical effect, and cost-effectiveness vary. Br MctlJ 1996; 313: 895-896.
30. Geoffroy P, Lalonde RL, Ahrens R, Clarke W, Hill MR, Vaughan LM, Grossman J. Clinical comparability of albuterol delivered by the breath-actuated inhaler (Spiros " ) and albuterol by MDI in patients with asthma. Ann Allergy Astlnna Inwnmol 1999; 82: 377-382.
31. Marshik PL, Rifle Y, Hendeles L. Response to inhaled beta-agonists during nocturnal attacks of asthma: a bioassay for relative potency. Am J Rcspir Crit Care Mcd 1997; 155: A672.
32. Hendeles L, Ahrens R, Clarke W, et al. Dose-response of inhaled albuterol during nocturnal bronchospasm. J Allergy Clin Inwnmol 1998; 101: S10.
33. Skinner C, Palmer KNV. Changes in specific airways conductance and forced expiratory volume in one second after a bronchodilator in normal subjects and patients with airways obstruction. Tliorax 1974; 29: 574-577.
34. Morice AH, Waterhouse JC, Peers EM, Parry-Billings M. Use of whole-body plethysmography to compare bronchodilator efficacy. Respiration 1998; 65: 120-124.
35. Lötvall J, Innian M, O'Byrne P. Measurement of airway hyperresponsiveness: new considerations. Thorax 1998; 53: 419-424.
36. Britton J. Symptoms and objective measures to define the asthma phenotype. Clin Exp Allergy 1998; 28(Suppl 1): 2-7.
37. Sterk PJ, Fabbri LM, Quanjer PhH, et al. Official statement of the European Respiratory Society: report working party: standardization of lung function tests; European Community for steel and coal. Airway responsiveness: standardized challenge testing with pharmacological, physical and sensitizing stimuli in adults. Ear RcspirJ 1993; 6(Suppl 16): 53-83.
38. Banik AN, Holgate ST. Problems and progress in measuring methacholine bronchial reactivity. Clin Exp Allergy 1998; 28(Suppl 1): 15-19.
39. Egbagbe E, Pavord ID, Wilding P, Thompson-Coon J, Tattersfield AE. Adenosine monophosphate and histamine induced bronchoconstriction: repeatability and protection by terbutaline. TVic'w.v 1997; 52: 239-243.
40. Cockcroft DW, Killian DN, Mellon JJA, Hargreave FE. Bronchial reactivity to inhaled histamine: a method and clinical survey. Clin Allergy 1977; 7: 235-243.
41. Juniper EF, Frith PA, Hargreave FE. Airway responsiveness to histamine and methacholine: relationship of minimum treatment to control symptoms of asthma. Thorax 1981; 36: 575-579.
42. Bootsma GP, Dekhuijzen PNR, Festen J, Mulder PGH, van Herwaarden CLA. Comparison of fluticasone propionate and beclomethasone dipropionate on direct and indirect measurements of bronchial hyperresponsiveness in patients with stable asthma. Tliarax 1995; 50: 1044-1050.
43. Kraan J, Koëter GH. v d Mark ThW, Sluiter HJ, de Vries K. Changes in bronchial hyperreactivity induced by 4 weeks of treatment with antiasthmatic drugs in patients with allergic asthma: a comparison between budesonide and terbutaline. J Allergy Clin Iiiwiiinol 1985; 76: 628-636.
44. Morice AH, Andrews B, Taylor M. Comparison of the effect on bronchial hyperresponsiveness of beclomethasone dipropionate administered via a novel niultidose dry powder inhaler or a conventional pressurised metered dose inhaler. Respiration 2000; 67: 298-305.
45. Newhouse MT, Pratt B, Clelland C, Tran C, Patel P. Protection against methacholine challenge: a method of establishing the dose response relationship of salbutamol delivered via dry powder inhaler (DPI) and metered dose inhaler (MDI). T/jom.v 1999; 54(Suppl 3): A30(P48).
46. Ahrens RC, Harris JB, Milavetz G, Annis L, Ries R. Use of bronchial provocation with histamine to compare the pharmacodynamics of inhaled albuterol and metaproterenol in patients with asthma.J^'/crt;}' Clin liiiiiiiuiol 1987; 79: 876-882.
47. Wong AG, O'Bynie I'M, Lindbladh C, Inman MD, Stahl E, Hargreave FE. Dose-response protective effect of salbutamol on methacholine airway responsiveness using pressurized metered dose inhalers and Turbuhalers. Can RcspirJ 1998; 5: 119-123.
48. Parameswaran KN, Inman MD, Ekholm DP, et al. Protection against methacholine bronchoconstriction to assess relative potency of inhaled βi-ag0'"5'- AinJ Respir Crit Care Mcd 1999; 160: 354-357.
49. Parameswaran K. Concepts of establishing clinical bioequivalence of chlorofluorocarbon and hydrofluoroalkane β-agonists. J Allergy Clin Immumol 1999; 104: S243-S245.
50. Martin RJ. Methacholine challenge testing: safety of low starting FEV1; Asthma clinical research network (ACRN). Chest 1997; 112: 53-56.
51. Approved drug products with therapeutic equivalence evaluations, 13th edn. Food and Drug Administration US Dept of Health and Human Services, US Govt Printing Office, Washington DC; vii-viii, 1993.
52. Snell NJC. Equivalence testing - the special case of inhaled medications. IntJ Phann Mcd 1998; 12: 245-246.
53. Webb J. Avoidance of Regulatory Delays for Inhalation roducts - Alternative Approaches to Product Development and Regulator)' Approval. Respir Drug Delivery VI. Interpharm Press (Buffalo Grove); 6: 457-459, 1998.
54. Pauwels R, Newman S, Borgström L. Airway deposition and airway effects of antiasthma drugs delivered from metered-dose inhalers. Em Respir J 1997; 10: 2127-2138.
55. Zanen P, Go TL, Lammers J-WJ. The optimal particle size for β-adrenergic aerosols in mild asthmatics. IntJ Pharm 1994; 107:211-217.
56. Padfield JM, Winterborn IK, Pover GM, Tattersfield A. Correlation between inertial impactor performance and clinical performance of a bronchodilator aerosol. J Phann Pharmacol 1983; 35(Suppl): 10P.
57. Snell NJC, Ganderton D. Assessing lung deposition of inhaled medications. Consensus Statement from a Workshop of the British Association for Lung Research (Institute of Biology, London, UK, 17 April 1998). Respir Mcd 1999; 93: 123-133.
58. Olsson B. Can in vitro measurements predict the lung deposition of dry-powders. J Aerosol Mcd 1997; 10: S13-S16.
59. Lipworth BJ. Pharmacokinetics of inhaled drugs. BrJ Clin Pharmacol 1996; 42: 697-705.
60. Clark DJ, Lipworth BJ. Lung bioavailability of chlorofluorocarbon free, dry powder and chlorofluorocarbon containing formulations of salbutamol. Br J Clin Pharmacol 1996; 41: 247-249.
61. Clark DJ, Gordon-Smith J, Mcl'hate G, Clark G, Lipworth BJ. Lung bioavailability of generic and innovator salbutaniol metered dose inhalers. Tliorax 1996; 51: 325-326.
62. Hindle M, Chrystyn H. Detemination of the relative bioavailability of salbutaniol to the lung following inhalation. Br J Clin Pharmacol 1992; 34: 311-315.
63. Hindle M, Peers EM, Parry-Billings M, Chrystyn H. Relative bioavailability of salbutaniol to the lung following inhalation via a novel dry powder inhaler and a standard metered dose inhaler. BrJ Clin Pliannacol 1997; 43: 336-338.
64. Tonilinson HS, Corlett SA, Chrystyn H. Effect of dose on the relative lung bioavailability of salbutaniol. J Aerosol Med 1995; 8: 127.
65. Chrystyn H, Alien MB, Corlett SA, Tonilinson HS. Simultaneous measurement of phnrniacodynamic and pharmacokinetic parameters which can be used to evaluate the equivalence of inhaled salbutaniol. Am J Respir Crit Care Med 1998; 157: A636.
66. Laube BL, Benedict GW, Dobs AS. Time to peak insulin level, relative bioavailability, and effect of site of deposition of nebulised insulin in patients with non-insulin-dependent diabetes mellitus. J Aerosol Mcd 1998; 11: 153-173.
67. Warren S. The measurement of pulmonary drug delivery using gamma scmtigraphy. BrJ Clin Pliannacol 2001; in press.
68. Nelson H, Kenip JP, Bieler S, Vaughan LM, Hill MR. Comparative efficacy and safety of albuterol sulfate Spiros inhaler and albuterol metered-dose inhaler in asthma. Chest 1999; 115: 329-335.
69. 2-agonists. Clin Exp Allergy 1992; 22:600-605.
70. Tattersfield AE. Tolerance to β-agonists. Bull Enr Physiopathol Rcspir 1985; 21: 1S-5S.
71. Food and Drug Administration. Chlorofluorocarbon propellants in self-pressurized containers; determinations that uses are no longer essential; request for comments. Federal Register 1997; 62: 10242-10246.